Literature DB >> 19242606

Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.

HyungJoon Cho1, Ellen Ackerstaff, Sean Carlin, Mihaela E Lupu, Ya Wang, Asif Rizwan, Joseph O'Donoghue, C Clifton Ling, John L Humm, Pat B Zanzonico, Jason A Koutcher.   

Abstract

In vivo knowledge of the spatial distribution of viable, necrotic, and hypoxic areas can provide prognostic information about the risk of developing metastases and regional radiation sensitivity and may be used potentially for localized dose escalation in radiation treatment. In this study, multimodality in vivo magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging using stereotactic fiduciary markers in the Dunning R3327-AT prostate tumor were performed, focusing on the relationship between dynamic contrast-enhanced (DCE) MRI using Magnevist (Gd-DTPA) and dynamic (18)F-fluoromisonidazole ((18)F-Fmiso) PET. The noninvasive measurements were verified using tumor tissue sections stained for hematoxylin/eosin and pimonidazole. To further validate the relationship between (18)F-Fmiso and pimonidazole uptake, (18)F digital autoradiography was performed on a selected tumor and compared with the corresponding pimonidazole-stained slices. The comparison of Akep values (kep = rate constant of movement of Gd-DTPA between the interstitial space and plasma and A = amplitude in the two-compartment model (Hoffmann U, Brix G, Knopp MV, Hess T and Lorenz WJ (1995). Magn Reson Med 33, 506-514) derived from DCE-MRI studies and from early (18)F-Fmiso uptake PET studies showed that tumor vasculature is a major determinant of early (18)F-Fmiso uptake. A negative correlation between the spatial map of Akep and the slope map of late (last 1 hour of the dynamic PET scan) (18)F-Fmiso uptake was observed. The relationships between DCE-MRI and hematoxylin/eosin slices and between (18)F-Fmiso PET and pimonidazole slices confirm the validity of MRI/PET measurements to image the tumor microenvironment and to identify regions of tumor necrosis, hypoxia, and well-perfused tissue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19242606      PMCID: PMC2647727          DOI: 10.1593/neo.81360

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  37 in total

1.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?

Authors:  C K Kuhl; P Mielcareck; S Klaschik; C Leutner; E Wardelmann; J Gieseke; H H Schild
Journal:  Radiology       Date:  1999-04       Impact factor: 11.105

Review 2.  Tumor hypoxia imaging.

Authors:  Inna Serganova; John Humm; Clifton Ling; Ronald Blasberg
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

Review 3.  Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

Authors:  P S Tofts
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

4.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole.

Authors:  W J Koh; J S Rasey; M L Evans; J R Grierson; T K Lewellen; M M Graham; K A Krohn; T W Griffin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

5.  Tumor oximetry: demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor.

Authors:  S Hunjan; D Zhao; A Constantinescu; E W Hahn; P P Antich; R P Mason
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-15       Impact factor: 7.038

Review 6.  Tumor oxygenation status as a prognostic marker.

Authors:  Chandrakala Menon; Douglas L Fraker
Journal:  Cancer Lett       Date:  2005-04-28       Impact factor: 8.679

7.  Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors.

Authors:  Pat Zanzonico; Jose Campa; Dolores Polycarpe-Holman; Gregor Forster; Ronald Finn; Steven Larson; John Humm; Clifton Ling
Journal:  Nucl Med Biol       Date:  2006-01       Impact factor: 2.408

Review 8.  Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis.

Authors:  G U Dachs; D J Chaplin
Journal:  Semin Radiat Oncol       Date:  1998-07       Impact factor: 5.934

9.  A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data.

Authors:  J J Casciari; M M Graham; J S Rasey
Journal:  Med Phys       Date:  1995-07       Impact factor: 4.071

Review 10.  An integrated MR/PET system: prospective applications.

Authors:  Heinz-Peter Schlemmer; Bernd J Pichler; Robert Krieg; Wolf-Dieter Heiss
Journal:  Abdom Imaging       Date:  2009-11
View more
  62 in total

1.  Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner.

Authors:  Thomas S C Ng; James R Bading; Ryan Park; Hargun Sohi; Daniel Procissi; David Colcher; Peter S Conti; Simon R Cherry; Andrew A Raubitschek; Russell E Jacobs
Journal:  J Nucl Med       Date:  2012-06-01       Impact factor: 10.057

2.  Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions.

Authors:  Kathrine Røe; Therese Seierstad; Alexandr Kristian; Lars Tore Gyland Mikalsen; Gunhild Mari Mælandsmo; Albert J van der Kogel; Anne Hansen Ree; Dag Rune Olsen
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

3.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

4.  Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.

Authors:  Louisa Bokacheva; Khushali Kotedia; Megan Reese; Sally-Ann Ricketts; Jane Halliday; Carl H Le; Jason A Koutcher; Sean Carlin
Journal:  NMR Biomed       Date:  2012-07-08       Impact factor: 4.044

5.  Automation of pattern recognition analysis of dynamic contrast-enhanced MRI data to characterize intratumoral vascular heterogeneity.

Authors:  SoHyun Han; Radka Stoyanova; Hansol Lee; Sean D Carlin; Jason A Koutcher; HyungJoon Cho; Ellen Ackerstaff
Journal:  Magn Reson Med       Date:  2017-07-20       Impact factor: 4.668

6.  GdDO3NI, a nitroimidazole-based T1 MRI contrast agent for imaging tumor hypoxia in vivo.

Authors:  Praveen K Gulaka; Federico Rojas-Quijano; Zoltan Kovacs; Ralph P Mason; A Dean Sherry; Vikram D Kodibagkar
Journal:  J Biol Inorg Chem       Date:  2013-11-27       Impact factor: 3.358

7.  Mapping Tumor Hypoxia In Vivo Using Pattern Recognition of Dynamic Contrast-enhanced MRI Data.

Authors:  Radka Stoyanova; Kris Huang; Kiri Sandler; Hyungjoon Cho; Sean Carlin; Pat B Zanzonico; Jason A Koutcher; Ellen Ackerstaff
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

Review 8.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

9.  Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury.

Authors:  Sahra Bodo; Cécile Campagne; Tin Htwe Thin; Daniel S Higginson; H Alberto Vargas; Guoqiang Hua; John D Fuller; Ellen Ackerstaff; James Russell; Zhigang Zhang; Stefan Klingler; HyungJoon Cho; Matthew G Kaag; Yousef Mazaheri; Andreas Rimner; Katia Manova-Todorova; Boris Epel; Joan Zatcky; Cristian R Cleary; Shyam S Rao; Yoshiya Yamada; Michael J Zelefsky; Howard J Halpern; Jason A Koutcher; Carlos Cordon-Cardo; Carlo Greco; Adriana Haimovitz-Friedman; Evis Sala; Simon N Powell; Richard Kolesnick; Zvi Fuks
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

10.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.